SLP
Simulations Plus, Inc.·Healthcare
15.37
1.721%(+0.26)
Market ClosedLast Updated: — ET
52W L: $11.0952W H: $34.01
SLP NEWS
businesswire.com
2d ago
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the 23rd Annual Craig-Hallum Institutional Investor Conference taking place in Minneapolis, Minnesota. Mr. O'Connor will host one-on-one meetings with institutional investors on Thurs.
benzinga.com
May 6
Simulations Plus Collaborates With Nvidia During AI Drug Modeling Push
Simulations Plus, Inc. (NASDAQ:SLP) shares are trading lower on Wednesday as the company announced a collaboration with NVIDIA Corp (NASDAQ:NVDA), aimed at enhancing GPU-accelerated simulation and AI-assisted workflows in drug development.
businesswire.com
May 6
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle. The collaboration brings together Simu.
zacks.com
Apr 28
Cadence Q1 Earnings Top Estimates, 2026 Revenue Outlook Raised
CDNS tops Q1 estimates, launches agentic AI Super Agents, hits a record $8B backlog, and raises its 2026 revenue outlook.
defenseworld.net
Apr 27
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of “Hold” from Brokerages
Simulations Plus, Inc. (NASDAQ: SLP - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the
businesswire.com
Apr 21
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (“Lonza”), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a me.
